Timely vaccine strain selection and genomic surveillance improves evolutionary forecast accuracy of seasonal influenza A/H3N2

John Huddleston[1*] **and Trevor Bedford**[1,2]

*For correspondence:
jhuddles@fredhutch.org (JH)

[1]Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA; [2]Howard Hughes Medical Institute, Seattle, WA, USA

Abstract   For the last decade, evolutionary forecasting models have influenced seasonal influenza vaccine design. These models attempt to predict which genetic variants circulating at the time of vaccine strain selection will be dominant 12 months later in the influenza season targeted by vaccination campaign. Forecasting models depend on hemagglutinin sequences from the WHO's Global Influenza Surveillance and Response System to identify currently circulating groups of related strains (clades) and estimate clade fitness for forecasts. However, the average lag between collection of a clinical sample and the submission of its sequence to the Global Initiative on Sharing All Influenza Data (GISAID) EpiFlu database is ~3 months. Submission lags complicate the already difficult 12-month forecasting problem by reducing understanding of current clade frequencies at the time of forecasting. Despite continued methodological improvements to long-term forecasting models, these constraints of a 12-month forecast horizon and 3-month average submission lags impose an upper bound on any model's accuracy. The global response to the SARS-CoV-2 pandemic revealed that the adoption of modern vaccine technology like mRNA vaccines can reduce how far we need to forecast into the future to 6 months or less and that expanded support for sequencing can reduce submission lags to GISAID to 1 month on average. To determine whether these public health policy changes could improve long-term forecasts for seasonal influenza, we quantified the effects of reducing forecast horizons and submission lags on the accuracy of forecasts for A/H3N2 populations. We found that reducing forecast horizons from 12 months to 6 or 3 months reduced average absolute forecasting errors to 25% and 50% of the 12-month average, respectively. Reducing submission lags provided little improvement to forecasting accuracy but decreased the uncertainty in current clade frequencies by 50%. These results show the potential to substantially improve the accuracy of existing influenza forecasting models through the public health policy changes of modernizing influenza vaccine development and increasing global sequencing capacity.

Introduction

Seasonal influenza virus infections cause approximately half a million deaths per year (*World Health Organization, 2014*). Vaccination provides the best protection against hospitalization and death, but the rapid evolution of the influenza surface protein hemagglutinin (HA) allows viruses to escape existing immunity and requires regular updates to influenza vaccines (*Petrova and Russell, 2018*). The World Health Organization (WHO) meets twice a year to decide on vaccine updates for

the Northern and Southern Hemispheres (*Morris et al., 2018*). The dominant influenza vaccine platform is an inactivated whole virus vaccine grown in chicken eggs (*Wong and Webby, 2013*) which takes 6 to 8 months to develop, contains a single representative vaccine virus per seasonal influenza subtype including A/H1N1pdm, A/H3N2, and B/Victoria (*Morris et al., 2018*), and for which only the HA protein content is standardized (*Yamayoshi and Kawaoka, 2019*). These constraints require the WHO to select a single virus per subtype that is immunologically-representative of the next season's dominant HA approximately 12 months before the peak of that next season. These selections depend on the diversity of currently circulating phylogenetic clades, groups of influenza viruses that all share a recent common ancestor. The WHO's understanding of that genetic diversity comes from HA sequences collected by the WHO's Global Influenza and Surveillance and Response System (GISRS) (*Hay and McCauley, 2018*) and submitted to the Global Initiative on Sharing All Influenza Data (GISAID) EpiFlu database (*Shu and McCauley, 2017*). The fastest evolving influenza subtype A/H3N2 accumulates 3–4 HA amino acid substitutions per year (*Smith et al., 2004*; *Kistler and Bedford, 2023*) such that the clades circulating 12 months after the vaccine decision can be antigenically distinct from clades that were circulating at the time of the decision.

Given the 12-month lag between the decision to update an influenza vaccine and the peak of the following influenza season, the vaccine composition decision is commonly framed as a long-term forecasting problem (*Lässig et al., 2017*). For this reason, the decision process is partially informed by computational models that attempt to predict the genetic composition of seasonal influenza populations 12 months in the future (*Morris et al., 2018*). The earliest of these models predicted future influenza populations from HA sequences alone (*Łuksza and Lässig, 2014*; *Neher et al., 2014*; *Steinbrück et al., 2014*). Recent models include phenotypic data from serological experiments (*Morris et al., 2018*; *Huddleston et al., 2020*; *Meijers et al., 2023*, *2025*). Since most serological experiments occur after genetic sequencing (*Hampson et al., 2017*) and all forecasting models depend on HA sequences to determine the viruses circulating at the time of a forecast, sequence availability is the initial limiting factor for any influenza forecasts. Unfortunately, the average lag between collection of a seasonal influenza A/H3N2 HA sample and submission of its sequence had been ~3 months in the era prior to the SARS-CoV-2 pandemic (*Figure 1*A). While long-term forecasting models continue to improve technically, the constraints of a 12-month forecast horizon and the availability of enough recent, representative HA sequences impose an upper bound on the accuracy of long-term forecasts.

The global response to the SARS-CoV-2 pandemic in 2020 showed the speed with which we can develop new vaccines and capture real-time viral genetic diversity. Decades of research on mRNA vaccines enabled the development of multiple effective vaccines a year after the emergence of SARS-CoV-2 (*Mulligan et al., 2020*; *Baden et al., 2021*). This mRNA-based vaccine platform also enabled the approval of booster vaccines targeting Omicron only 3 months after the recommendation of an Omicron-based vaccine candidate (*Grant et al., 2023*). In parallel to vaccine development, expanded funding and capacity building for viral genome sequencing enabled unprecedented dense sampling of a pathogen's genetic diversity over a short period of time (*Chen et al., 2022*). By 2021, the average time between collection of a SARS-CoV-2 sample and submission of the sample's genome sequence to GISAID EpiCoV database had decreased to approximately 1 month (*Brito et al., 2022*). This reduction in submission lags reflects both increased emergency funding and the sustained efforts by more public health organizations to adopt best practices for genomic epidemiology (*Kalia et al., 2021*; *Black et al., 2020*). Assessments of SARS-CoV-2 short-term forecasts have shown how such reductions in forecast horizon and submission lags can improve the accuracy of short-term forecasts and real-time estimates of clade frequencies (*Abousamra et al., 2024*).

These technological and public health policy changes in response to SARS-CoV-2 suggest that we could realistically expect the same outcomes for seasonal influenza. Work on mRNA vaccines for influenza viruses dates back over a decade (*Petsch et al., 2012*; *Brazzoli et al., 2016*; *Pardi et al., 2018*; *Feldman et al., 2019*), and multiple vaccines have completed phase 3 trials by early 2025 (*Soens*

et al., 2025; *Pfizer, 2022*). A switch from the current egg-based inactivated virus vaccines to mRNA vaccines could reduce the time between vaccine design decisions and the peak influenza season from 12 months to 6 months. Similarly, the expanded global capacity for sequencing SARS-CoV-2 genomes could reasonably extend to broader and more rapid genomic surveillance for seasonal influenza, reducing submission lags from 3 months to 1 month on average. Even in the years immediately after the onset of the SARS-CoV-2 pandemic, we have observed a trend toward a reduced average submission lag of 2.5 months that we would expect from increased global capacity for genome sequencing (*Figure 1—figure Supplement 1*).

In this work, we tested the effects of similar reductions in forecast horizons and submission lags on the accuracy of long-term forecasts for seasonal influenza. Building on our previously published forecasting framework (*Huddleston et al., 2020*), we performed a retrospective analysis of HA sequences from simulated and natural A/H3N2 populations. For each population type, we produced forecasts from 12, 9, 6, and 3 months prior to a given influenza season (*Figure 1*A). We made each forecast under three different submission lag scenarios including a realistic lag (3 months on average), an ideal lag (1 month on average), and no lag (*Figure 1*B). First, we measured the accuracy and precision of forecasts under these different scenarios by calculating the genetic distance between predicted and observed future populations using the same earth mover's distance metric that we originally used to train our forecasting models (*Rubner et al., 1998*). Next, we calculated the effect of forecast horizon and submission lags on clade frequencies which are the values we use to communicate predictions to WHO decision-makers (*Huddleston et al., 2024*). We quantified the effect of reduced submission lags on initial clade frequencies, and we calculated forecast accuracy as the difference between predicted and observed clade frequencies of future populations. Finally, we calculated the relative improvement in forecast accuracy produced by different realistic interventions including reduced vaccine development time, reduced submission lags, and the combination of both. In this way, we show the potential to improve the accuracy of existing long-term forecasting models and, thereby, the quality of vaccine design decisions by simplifying the forecasting problem through realistic societal changes.

Results

Reducing forecast horizons and submission lags decreases distances between predicted and observed future populations

Previously, we trained long-term forecasting models that minimized the genetic distance between predicted and observed future populations of HA sequences (*Huddleston et al., 2020*). We predicted each population 12 months in the future based on the frequencies and fitness estimates of HA sequences in the current population. We calculated the distance between predicted and observed future populations with the earth mover's distance metric (*Rubner et al., 1998*). This metric provided an average genetic distance between amino acid sequences of the two populations weighted by the frequencies of sequences in each population. This approach allowed us to measure forecasting accuracy without first defining phylogenetic clades, a process that can borrow information from the future or change clade definitions between initial and future timepoints. We identified the best forecasting models as those that minimized this distance between populations. The most accurate sequence-only model for the 12-month forecast horizon estimated fitness with local branching index (LBI) (*Neher et al., 2014*) and mutational load (*Łuksza and Lässig, 2014*). As a positive control, we calculated the posthoc empirical fitness of each initial population based on the composition of the corresponding future population. These empirical fitnesses provided the lower bound on the earth mover's distance which represented the number of amino acid substitutions accumulated between populations.

To understand the effects of reducing forecast horizons and submission lags on long-term forecast accuracy, we produced forecasts 3, 6, 9, and 12 months into the future using HA sequences available at each initial timepoint under each submission lag scenario including no lag, ideal lag

Figure 1. Model of forecast horizons and submission lags. A) Long-term forecasting models historically predicted 12 months into the future from April and October because of the time required to develop and distribute a new vaccine (*Łuksza and Lässig, 2014*). We tested three additional shorter forecast horizons in three-month intervals of 9, 6, and 3 months prior to the same time in the future season. For each forecast horizon, we calculated the accuracy of forecasts under each of the three submission lags described below including no lag, realistic lag, and ideal lag. B) Observed lags in days between collection of viral samples and submission of corresponding HA sequences to GISAID (purple) for samples collected in 2019 have a mean of 98 days (approximately 3 months). A gamma distribution fit to the observed lag distribution with a similar mean and shape (green) represents a realistic submission lag that we sampled from to assign "submission dates" to simulated and natural A/H3N2 populations. A gamma distribution with a mean that is one third of the realistic distribution (orange) represents an ideal submission lag analogous to the 1-month average observed lags for SARS-CoV-2 genomes. Retrospective analyses including fitting of forecasting models typically filter HA sequences by collection date instead of submission dates in which case there is no lag (blue).

Figure 1—figure supplement 1. Distribution of submission lags in days for the pre-pandemic era (2019-2020) and pandemic era (2022-2023)

Figure 1—figure supplement 2. Number and proportion of A/H3N2 sequences available per timepoint and lag type

Figure 1—figure supplement 3. Number and proportion of simulated A/H3N2-like sequences available per timepoint and lag type

Figure 1—figure supplement 4. Number of all available sequences per region and year and proportion of sequences sampled by two different subsampling methods

Figure 1—source data 1. Distribution of lags between sample collection and sequence submission in prepandemic and pandemic eras; see `distribution_of_submission_lags.csv` at https://doi.org/10.5281/zenodo.17259448.

(~1-month average), and realistic lag (~3-month average) (*Figure 1*, *Figure 1—figure Supplement 2*, *Figure 1—figure Supplement 3*). For both natural and simulated populations, we assigned ideal and realistic lags to each sequence from the modeled distributions in *Figure 1*B. This approach allowed us to assign uncorrelated lag values to both population types while avoiding the biases associated

¹⁴⁴ with historical submission patterns for natural A/H3N2 HA sequences. For natural A/H3N2 pop-
¹⁴⁵ ulations, we used the best sequence-only forecasting model, LBI and mutational load, which we
¹⁴⁶ previously trained on 12-month forecasts without any submission lag. For simulated A/H3N2-like
¹⁴⁷ populations, we used the observed fitness per sample provided by the simulator. For each forecast
¹⁴⁸ horizon and submission lag type, we calculated the earth mover's distance between the predicted
¹⁴⁹ future populations under the given lag scenario and the observed future populations without any
¹⁵⁰ lag in sequence availability. As a control, we also calculated the optimal distance between initial
¹⁵¹ and future populations based on posthoc empirical fitness of the initial population. We anticipated
¹⁵² that reducing either the forecast horizon or the submission lag would reduce the distance to the
¹⁵³ future in amino acids (AAs), representing increased accuracy of the forecasting models.

¹⁵⁴ We found that reducing the forecast horizon from the current standard of 12 months linearly
¹⁵⁵ reduced the distance to the future population predicted by the LBI and mutational load model
¹⁵⁶ (*Figure 2*). Under the all three submission lag scenarios, the distance to the future reduced by ap-
¹⁵⁷ proximately 1 AA on average for each 3-month reduction in forecast horizon (*Table 1*). We observed
¹⁵⁸ the greatest average reduction in distance to the future (∼1.4 AAs) between the 6- and 3-month
¹⁵⁹ forecast horizons. Reducing the forecast horizon also noticeably reduced the variance per time-
¹⁶⁰ point in predicted future populations across all lag scenarios (*Figure 2*). For example, the standard
¹⁶¹ deviation of distances to the future reduced from ∼2.6 AAs at the 12-month horizon to ∼1 AA at the
¹⁶² 3-month horizon (*Table 1*). We observed the same patterns for forecasts of simulated A/H3N2-like
¹⁶³ populations (*Figure 2—figure Supplement 1*) and optimal distances to the future for natural and
¹⁶⁴ simulated populations (*Figure 2—figure Supplement 2* and *Figure 2—figure Supplement 3*). Thus,
¹⁶⁵ reducing how far we have to predict into the future increased both forecast accuracy and precision.

	Distance to future (mean +/- std dev AAs)		
Horizon	No lag	Ideal lag	Realistic lag
3	2.91 +/- 0.86	3.32 +/- 0.96	3.85 +/- 1.05
6	4.44 +/- 1.39	4.74 +/- 1.54	5.03 +/- 1.66
9	5.48 +/- 2.05	5.84 +/- 2.14	6.04 +/- 2.15
12	6.45 +/- 2.72	6.77 +/- 2.80	6.78 +/- 2.61

Table 1. Distance to the future in amino acids (mean +/- standard deviation AAs) by forecast horizon (in
months) and submission lag for A/H3N2 populations.

¹⁶⁶ In contrast, we found that reducing submission lags from a ∼3-month average lag in the re-
¹⁶⁷ alistic scenario to a ∼1-month average lag in the ideal scenario had a weaker effect on distance
¹⁶⁸ to the future. At the 12-month forecast horizon, the ideal and realistic lag scenarios produced
¹⁶⁹ similar predictions, with the only noticeable improvement observed under the scenario without
¹⁷⁰ any submission lags (*Figure 2*). As the forecast horizon decreased, the effect of submission lags
¹⁷¹ appeared more prominent, with the greatest effect of reduced lags observed at the 3-month fore-
¹⁷² cast horizon. However, the average improvement from the realistic to the ideal submission lag
¹⁷³ scenario at the 3-month horizon was still only ∼0.3 AAs (*Table 1*). Reducing submission lags also
¹⁷⁴ had little effect on the variance per timepoint in predicted future populations. Interestingly, we
¹⁷⁵ observed a stronger effect of reducing submission lags in simulated A/H3N2-like populations, with
¹⁷⁶ the best average improvement between realistic and ideal lags of ∼0.7 AAs at the 3-month horizon
¹⁷⁷ (*Figure 2—figure Supplement 1*). As with natural A/H3N2 populations, the effect of reducing sub-
¹⁷⁸ mission lags appeared to increase as the forecast horizon decreased. These results indicate that
¹⁷⁹ reducing submission lags may have little effect under the current 12-month forecast approach
¹⁸⁰ used for influenza vaccine composition, but reducing submission lags should become increasingly
¹⁸¹ important as we forecast from closer to future influenza populations.

Figure 2. Distance to the future per timepoint (AAs) for natural A/H3N2 populations by forecast horizon and submission lag type based on forecasts from the local branching index (LBI) and mutational load model. Each point represents a future timepoint whose population was predicted from the number of months earlier corresponding to the forecast horizon. Points are colored by submission lag type including forecasts made with no lag (blue), an ideal lag (orange), and a realistic lag (green).

Figure 2—figure supplement 1. Distance to the future for simulated A/H3N2-like populations

Figure 2—figure supplement 2. Optimal distance to the future for natural A/H3N2 populations

Figure 2—figure supplement 3. Optimal distance to the future for simulated A/H3N2-like populations

Figure 2—source data 1. Distance to the future for natural A/H3N2 populations; see

`h3n2_distances_to_the_future.csv` at https://doi.org/10.5281/zenodo.17259448.

Figure 2—source code 1. Jupyter notebook used to produce this figure and the supplemental figure:

`workflow/notebooks/plot-distances-to-the-future-by-delay-type-and-horizon-for-population.py.ipynb`.

Reducing submission lags improves estimates of current clade frequencies

Although the distance between predicted and observed future populations in amino acids provides an unbiased metric to optimize forecasting models, in practice, we use these models to forecast clade frequencies. We predict each clade's future frequency as the sum of predicted future frequencies for each HA sequence in the clade. We calculate these sequence-specific future frequencies as the initial sequence frequency times the estimated sequence fitness (*Łuksza and Lässig, 2014*; *Huddleston et al., 2020*). Given the importance of initial clade frequencies in these forecasts, we tested the effect of submission lags on current clade frequency estimates. For each timepoint and clade with a frequency greater than zero under the scenario without lags, we calculated the clade frequency error as the difference between clade frequency without submission lags and the frequency with either an ideal or realistic lag. Positive error values represented underestimation of current clades, while negative values represented overestimation.

Across all clade frequencies, we found that errors in current clade frequencies for A/H3N2 appeared normally distributed with lower variance in the ideal lag scenario than under realistic lags (*Figure 3*A and B). Of the 822 clades under the scenario without lags, 613 (75%) had a frequency less than 10%, representing small, emerging clades. The remaining 209 (25%) had a frequency of 10% or greater, representing larger clades that could be more likely to succeed. To understand whether

lags had different effects on these small and large clades, respectively, we inspected clades from
these latter two groups separately. For small clades, errors under ideal lags ranged from -4% to
4% with a standard deviation of 1%, while realistic lags produced errors ranging from -8% to 7%
with a standard deviation of 2% (*Figure 3*C). We did not observe a bias toward underestimation or
overestimation of initial small clade frequencies under either lag scenario. For large clades, errors
under ideal lag ranged from -9% to 14% with a standard deviation of 3% (*Figure 3*D). Errors un-
der realistic lags ranged from -16% to 29% with a standard deviation of 6%. We observed a slight
bias toward underestimation of large clades under the realistic lag scenario, with a median error
of 1%. These results show that reducing submission lags for natural A/H3N2 populations from a
3-month average to a 1-month average could reduce the bias toward underestimated large clade
frequencies and reduce the standard deviation of all current clade frequency errors by 50%.
Lagged submissions similarly affected clade frequencies for simulated A/H3N2-like populations
(*Figure 3—figure Supplement 1*). Small clade errors under ideal lags ranged from -4% to 6% (stan-
dard deviation of 1%) and under realistic lags ranged from -9% to 8% (standard deviation of 2%)
(*Figure 3—figure Supplement 1*C). For large clades, errors under ideal lags ranged from -8% to 18%
(standard deviation of 3%) and under realistic lags from -14% to 40% (standard deviation of 7%)
(*Figure 3—figure Supplement 1*D). As with natural A/H3N2 populations, we observed a slight bias
in simulated populations under realistic lags toward underestimation of large clade frequencies
with a median error of 2%. We also observed a similar reduction in standard deviation of cur-
rent frequency errors for these simulated A/H3N2-like populations when switching from realistic
to ideal submission lags.

Reducing forecast horizons increases the accuracy and precision of clade frequency forecasts

Next, we estimated the effects of different forecast horizons and submission lags on the accu-
racy of clade frequency forecasts. As with the current clade frequency analysis, we analyzed small
clades (<10% initial frequency) and large clades (≥10% initial frequency) separately. For each com-
bination of initial timepoint, future timepoint, and lag scenario (*Figure 1*A), we calculated initial
and predicted future frequencies for all clades present under the given lag and then calculated the
corresponding observed future frequencies without lag for clades that descended from the clades
present at the initial timepoint. We calculated the error in forecast frequencies as the difference
between predicted future frequencies under the given lag scenario and observed future frequen-
cies without any lag. We used absolute forecast errors to evaluate forecast accuracy and overall
forecast errors to evaluate forecast bias.
Absolute forecast errors trended strongly toward values less than 30% with long tails reaching
80% for both small and large clades (*Figure 4*). Each 3-month reduction of the forecast horizon lin-
early reduced the variance in forecast errors, but mean and median absolute errors only improved
after reducing the forecast horizon below 9 months (*Figure 4* and *Table 2*). For small clades, reduc-
ing the forecast horizon most noticeably reduced the range of errors, while reducing submission
lags had little effect (*Figure 4*A). For large clades, almost all decreases in forecast horizon and sub-
mission lag (except lags at the 12-month horizon) reduced the standard deviation of absolute fore-
cast errors (*Figure 4*B). Overall, reducing the forecast horizon had a greater effect on the mean,
median, and standard deviation of absolute forecast errors than reducing submission lags. For
example, the standard deviation of absolute errors at the 12-month horizon under realistic sub-
mission lags was 23%, while the standard deviation for the 6-month horizon under realistic lags
was 14% (*Table 2*). In contrast, the standard deviation at the 12-month horizon under ideal submis-
sion lags did not change from the realistic lags at 23%, and the average absolute error increased by
1% from 20%. For all other forecast horizons, reducing the submission lags from realistic to ideal
only reduced the mean and standard deviation of absolute errors by 1–2%. We observed the same
general patterns in simulated populations (*Figure 4—figure Supplement 1*).
The majority of forecast frequency errors appeared to be normally distributed, indicating lit-

Figure 3. Clade frequency errors for natural A/H3N2 clades at the same timepoint calculated as the difference between clade frequencies without submission lag and corresponding frequencies with either A) ideal or B) realistic submission lags. Distributions of frequency errors appear normally distributed in both lag scenarios for both C) small clades (>0% and <10% frequency) and D) large clades (≥10%). Dashed lines indicate the median error from the distribution of the lag type with the same color.

Figure 3—figure supplement 1. Current clade frequency errors for simulated A/H3N2-like populations

Figure 3—source data 1. Current and future clade frequencies for natural A/H3N2 populations by forecast horizon and submission lag type; see `h3n2_clade_frequencies.csv` at https://doi.org/10.5281/zenodo.17259448.

Figure 3—source code 1. Jupyter notebook used to produce this figure and the supplemental figure: `workflow/notebooks/plot-current-clade-frequency-errors-by-delay-type-for-populations.py.ipynb`.

Figure 4. Absolute forecast clade frequency errors for natural A/H3N2 populations by forecast horizon in months and submission lag type (none, ideal, or observed) for A) small clades (<10% initial frequency) and B) large clades (≥10% initial frequency).

Figure 4—figure supplement 1. Absolute forecast clade frequency errors for simulated A/H3N2-like populations.

Figure 4—figure supplement 2. Forecast clade frequency errors for natural A/H3N2 populations.

Figure 4—figure supplement 3. Forecast clade frequency errors for simulated A/H3N2-like populations.

Figure 4—source code 1. Jupyter notebook used to produce this figure and the supplemental figures:
`workflow/notebooks/plot-forecast-clade-frequency-errors-by-delay-type-and-horizon-for-population.py.ipynb`

249 tle bias toward over- or underestimating future clade frequencies (*Figure 4—figure Supplement 2*
250 and *Figure 4—figure Supplement 3*). This pattern matched our expectation that at any given initial
251 timepoint the overestimation of one clade's future frequency must cause an underestimation of
252 another current clade's future frequency. However, we observed a long tail of small clades with
253 underestimated future frequencies at all forecast horizons, indicating that correctly predicting the

		Clade frequency error (%)					Absolute frequency error (%)		
Horizon	Lag type	Mean	Median	Std Dev	Min	Max	Mean	Median	Std Dev
3	none	1	0	9	-28	28	7	6	6
3	ideal	1	0	11	-32	36	8	6	7
3	realistic	1	0	13	-31	50	10	7	9
6	none	1	0	17	-48	45	12	9	11
6	ideal	1	0	19	-50	53	13	9	13
6	realistic	1	0	20	-52	75	15	12	14
9	none	0	-1	23	-66	59	16	10	17
9	ideal	1	-1	25	-67	58	18	11	18
9	realistic	1	-1	26	-67	79	19	12	19
12	none	0	0	30	-82	76	20	10	22
12	ideal	1	0	31	-80	74	21	9	23
12	realistic	0	0	31	-78	78	20	12	23

Table 2. Errors in clade frequencies between observed and predicted values by forecast horizon (in months) and submission lag for A/H3N2 clades with an initial frequency ≥10% under the given lag scenario.

growth of small clades remains more difficult than predicting their decline (*Figure 4—figure Supplement 2*A). The strongest effect of reducing submission lags was the reduction in maximum error, corresponding to reduction in underestimation of large clades. The switch from realistic to ideal lags at 12-, 9-, 6-, and 3-month horizons reduced the maximum forecast error by 4%, 21%, 22%, and 14%, respectively (*Table 2*). These results show that reducing submission lags can substantially lower the upper bound for forecasting errors.

Reduced vaccine development time provides the best improvement in forecast accuracy of available realistic interventions

Although we have investigated the effects of a range of forecast horizons and submission lags, not all of these scenarios are currently realistic. The most we can hope to reduce the forecast horizon with current mRNA vaccine technology is from 12 months to 6 months and the most we could reduce submission lags would be from an average of 3 months to 1 month (*Grant et al., 2023*). In practice, we wanted to know how much a reduction in forecast horizon or submission lag could improve the accuracy of forecasts to each future timepoint. To determine the effects of realistic interventions on forecast accuracy, we inspected the reduction in total absolute forecast error per future timepoint associated with improved vaccine development (reducing forecast horizon from 12 months to 6 months), improved genomic surveillance (reducing lags from a 3-month average to 1 month), and the combination of both improvements. We selected all forecasts with a 12-month horizon and a realistic lag, to represent current forecast conditions or "the status quo". For the same future timepoints present in the status quo conditions, we selected the corresponding forecasts for a 6-month horizon and a realistic lag, a 12-month horizon and an ideal lag, and 6-month horizon and an ideal lag. Since forecasts between different initial and future timepoints could be represented by different clades, we could not compare forecasts for specific clades between interventions. Instead, we calculated the total absolute clade frequency error per future timepoint under each intervention and calculated the improvement in forecast accuracy as the difference in total error between the status quo and each intervention. In addition to this clade-based analysis, we also estimated effects of interventions on the difference in distance to the future between different scenarios for both estimated and empirical fitnesses. For all analyses, positive values represented improved forecast accuracy under a given intervention scenario and negative values represented a reduction in accuracy.

Figure 5. Improvement of clade frequency errors for A/H3N2 populations between the status quo (12-month forecast horizon and realistic submission lags) and realistic interventions of improved vaccine development (reducing 12-month to 6-month forecast horizon), improved surveillance (reducing submission lags from 3 months on average to 1 month), or a combination of both interventions. We measured improvements from the status quo as the difference in total absolute clade frequency error per future timepoint. Positive values indicate increased forecast accuracy, while negative values indicate decreased accuracy. Each point represents the improvement of forecasts for a specific future timepoint under the given intervention. Horizontal dashed lines indicate median improvements. Horizontal dotted lines indicate upper and lower quartiles of improvements.

Figure 5—figure supplement 1. Distribution of total absolute clade frequency errors summed across clades per future timepoint for A/H3N2 populations.

Figure 5—figure supplement 2. Improvement of clade frequency errors for simulated A/H3N2-like populations.

Figure 5—figure supplement 3. Distribution of total absolute clade frequency errors summed across clades per future timepoint for simulated A/H3N2-like populations.

Figure 5—figure supplement 4. Improvement of distances to the future (AAs) for A/H3N2 populations between the status quo (12-month forecast horizon and realistic submission lags) and realistic interventions.

Figure 5—figure supplement 5. Improvement of distances to the future (AAs) for simulated A/H3N2-like populations between the status quo (12-month forecast horizon and realistic submission lags) and realistic interventions.

Figure 5—source data 1. Differences in total absolute clade frequency error per future timepoint and clade between the status quo and realistic interventions for A/H3N2 populations; see
`h3n2_effects_of_realistic_interventions.csv` at https://doi.org/10.5281/zenodo.17259448.

Figure 5—source code 1. Jupyter notebook used to produce effects of interventions on total absolute clade frequency errors
`workflow/notebooks/plot-forecast-clade-frequency-errors-by-delay-type-and-horizon-for-population.py.ipynb`

Figure 5—source code 2. Jupyter notebook used to produce effects of interventions on distances to the future:
`workflow/notebooks/plot-distances-to-the-future-by-delay-type-and-horizon-for-population.py.ipynb`

Both interventions with improved vaccine development increased forecast accuracy for the ma-
jority of future timepoints (*Figure 5*, *Table 3*, and *Figure 5—figure Supplement 1*). Improving vac-
cine development alone increased total forecast accuracy by 53% on average, while the addition
of improved genomic surveillance under that 6-month forecast horizon increased total forecast ac-
curacy by 54% on average. In contrast, the intervention that only improved genomic surveillance
decreased forecast accuracy by an average of 11%. Based on the distributions of total absolute
forecast error per future timepoint, we would expect improved genomic surveillance to improve

| | Forecast accuracy improvement (%) | | | Timepoints improved | |
Intervention	Mean	Median	Std Dev	Total	Proportion
improved vaccine	53	49	112	19	0.61
improved surveillance	-11	-13	56	10	0.32
improved vaccine and surveillance	54	29	124	18	0.58

Table 3. Improvement in A/H3N2 clade frequency forecast accuracy under realistic interventions of improved vaccine development (reducing 12-month to 6-month forecast horizon), improved surveillance (reducing submission lags from 3 months on average to 1 month), or a combination of both interventions. We measured improvements from the status quo (12-month forecast horizon and 3-month average submission lag) as the difference in total absolute clade frequency error per future timepoint and the number and proportion of future timepoints for which forecasts improved under the intervention.

forecast accuracy at a forecast horizon of 3 months (*Figure 5—figure Supplement 1*). We observed similar effects of interventions in simulated A/H3N2-like populations except that the average effect of reducing submission lags alone was positive for these populations (*Figure 5—figure Supplement 2* and *Figure 5—figure Supplement 3*). When we calculated the effects of interventions on distances to the future instead of total absolute clade frequency errors, we observed the same patterns for natural and simulated populations (*Figure 5—figure Supplement 4* and *Figure 5—figure Supplement 5*). Based on these results, the single most valuable intervention we could make to improve forecast accuracy would be to reduce the forecast horizon to 6 months or less through more rapid vaccine development. However, as we reduce the forecast horizon, reducing submission lags should have a greater effect on improving forecast accuracy.

We hypothesized that the decrease in average accuracy of natural A/H3N2 forecasts under the improved genomic surveillance intervention could reflect the bias of the LBI and mutational load fitness metrics. For example, we previously showed how LBI fitness estimates can overestimate the future growth of large clades (*Huddleston et al., 2020*). Adding more sequences at initial timepoints where LBI already overestimates clade success could increase the LBI of those clades and exacerbate the overestimation. To test this hypothesis, we calculated the effects of the same interventions on the optimal distances to the future for both natural and simulated populations. Since optimal distances reflected the empirical fitnesses of the initial populations, the effects of interventions should be independent of biases from fitness metrics. We expected all interventions to maintain or improve the optimal distance to the future without any cases where an intervention decreased accuracy.

As expected, all interventions improved on the optimal distance to the future for both populations (*Figure 6* and *Figure 6—figure Supplement 1*). For natural A/H3N2 populations, the average improvement of the vaccine intervention was 1.1 AAs and the improvement of the surveillance intervention was 0.27 AAs or approximately 25% of the vaccine intervention. The average improvement of both interventions was only slightly less than additive at 1.28 AAs. To verify the robustness of these results, we replicated our entire analysis of A/H3N2 populations using a subsampling scheme that tripled the number of viruses selected per month from 90 to 270 (*Figure 1—figure Supplement 4*C). We found the same pattern with this replication analysis, with average improvements of 0.93 AAs for the vaccine intervention, 0.21 AAs for the surveillance intervention, and 1.14 AAs for both interventions (*Figure 6—figure Supplement 2*). These effects of realistic interventions appeared consistent across the range of genetic diversity at future timepoints (*Figure 6—figure Supplement 3*) and for future seasons occurring in both Northern and Southern Hemispheres (*Figure 6—figure Supplement 4*). We noted a slightly greater median improvement in forecast accuracy associated with both improved vaccine interventions for the Southern Hemisphere seasons (1.03 and 1.42 AAs) compared to the Northern Hemisphere seasons (0.74 and 0.93 AAs). These results confirmed the relatively stronger effect of reducing forecast horizons compared to submission lags.

 They also confirmed that reducing submission lags can improve forecast-
 ing conditions. For this reason, we expect that simultaneous improvements to forecasting models
 and genomic surveillance will have a mutually beneficial effect on forecast accuracy.

Figure 6. Improvement of optimal distances to the future (AAs) for A/H3N2 populations between the status quo (12-month forecast horizon and realistic submission lags) and realistic interventions of improved vaccine development (reducing 12-month to 6-month forecast horizon), improved surveillance (reducing submission lags from 3 months on average to 1 month), or a combination of both interventions. We measured improvements from the status quo as the difference in optimal distances to the future per future timepoint. Positive values indicate increased forecast accuracy, while negative values indicate decreased accuracy. Each point represents the improvement of forecasts for a specific future timepoint under the given intervention. Horizontal dashed lines indicate median improvements. Horizontal dotted lines indicate upper and lower quartiles of improvements.

Figure 6—figure supplement 1. Improvement of optimal distances to the future (AAs) for simulated A/H3N2-like populations between the status quo (12-month forecast horizon and realistic submission lags) and realistic interventions.

Figure 6—figure supplement 2. Improvement of optimal distances to the future (AAs) for A/H3N2 populations sampled with higher density sampling (270 viruses per month).

Figure 6—figure supplement 3. Improvement of optimal distances to the future (AAs) for A/H3N2 populations compared to the Shannon entropy of clade frequencies at the future timepoint being forecast to.

Figure 6—figure supplement 4. Improvement of optimal distances to the future (AAs) for A/H3N2 populations by intervention and the hemisphere with an active season during the future timepoint being predicted.

Figure 6—source data 1. Differences in optimal distances to the future per future timepoint between the status quo and realistic interventions for A/H3N2 populations; see

`h3n2_optimal_effects_of_realistic_interventions_on_distances_to_the_future.csv` at
https://doi.org/10.5281/zenodo.17259448.

Figure 6—source code 1. Python notebook used to produce optimal effects of interventions on distances to the future:

`workflow/notebooks/plot-distances-to-the-future-by-delay-type-and-horizon-for-population.py.ipynb.`

Figure 6—source code 2. Python notebook used to plot optimal effects by future clade entropy:

`workflow/notebooks/plot-optimal-effects-of-interventions-by-clade-entropy.py.`

Figure 6—source code 3. Python notebook used to plot optimal effects by hemisphere:

`workflow/notebooks/plot-optimal-effects-of-interventions-by-hemisphere.py.`

Discussion

In this work, we showed that realistic public health policy changes that decrease the time to develop new vaccines for seasonal influenza A/H3N2 and decrease submission lags of HA sequences to public databases could improve our estimates of future and current populations, respectively. We confirmed that forecasts became more accurate and more precise with each 3-month reduction in forecast horizon from the status quo of 12 months. Although decreasing submission lags only marginally improved long-term forecast accuracy, shorter lags increased the accuracy of current clade frequency estimates, reduced the bias toward underestimating current and future frequencies of larger clades, and improved forecasts 3 months into the future. Under a realistic scenario where a shorter vaccine development timeline allowed us to forecast from 6 months before the next season, we found a 53% average improvement in forecasts of total absolute clade frequency and a 25% reduction in average absolute forecast frequency errors for large clades from 20% to 15%. We confirmed these effects with a previously validated forecasting model using both simulated and natural populations and two different metrics of forecast accuracy including earth mover's distances between populations and clade frequencies. Since all models to date rely on currently available HA sequences to determine the clades to be forecasted, we expect that decreasing forecast horizons and submission lags will have similar relative effect sizes across all forecasting models including those that integrate phenotypic and genetic data.

Even without these recommended improvements to vaccine development and sequence submissions, these results inform important next steps to improve forecasting models. Current and future frequency estimates should be presented with corresponding uncertainty intervals. From this work, we know that our current frequency estimates for large clades ($\geq$10% frequency) under realistic submission lags have a wide range of errors (-16% to 29%). Similarly, the range of 12-month forecast frequency errors under realistic lags include overestimates by up to 78% and underestimates up to 78%. Long-term forecasts with incomplete current data are highly uncertain by their nature. To support informed decisions about vaccine updates, we must communicate that uncertainty of the present and future to decision-makers. One simple immediate strategy to provide these uncertainty estimates is to estimate current and future clade frequencies from count data with multinomial probability distributions.

Another immediate improvement would be to develop models that can use all available data in a way that properly accounts for geographic and temporal biases. For example, virus samples from North America and Europe are overrepresented in the GISAID EpiFlu database, while samples from Africa and Asia are underrepresented (*Figure 1—figure Supplement 4*). As new H3N2 epidemics often originate from East and Southeast Asia and burn out in North America and Europe (*Bedford et al., 2015*), models that do not account for this geographic bias are more likely to incorrectly predict the success of lower fitness variants circulating in overrepresented regions and miss higher fitness variants emerging from underrepresented regions. Additionally, the number of H3N2 HA sequences per year in the GISAID EpiFlu database has increased consistently since 2010, creating a temporal bias where any given season a model forecasts to will have more sequences available than the season from which forecasts occur. The model we used in this study does not explicitly account for geographic variability of viral fitness and relies on time-scaled phylogenetic trees which can be computationally costly to infer for large sample sizes. As a result, we needed to evenly sample the diversity of currently circulating viruses to produce unbiased trees in a reasonable amount of time. Models that could estimate viral fitness per geographic region without inferring trees could use more available sequence data and reduce the uncertainty in current and future clade frequencies.

Finally, we could improve existing models by changing the start and end times of our long-term forecasts. We could change our forecasting target from the middle of the next season to the beginning of the season, reducing the forecast horizon from 12 to 9 months. We could also start forecasting from one month prior to the current date to minimize the effect of submission lags on

381 our estimates of the current global influenza population.

382 Despite the small effect that reducing sequence submission lags had on long-term forecasting
383 accuracy, we still see a need to continue funding global genomic surveillance at higher levels than
384 the pre-pandemic period. Compared to estimates of current viral diversity, forecasts of future
385 influenza populations only represent one component of the overall decision-making process for
386 vaccine development. For example, virologists must choose potential vaccine candidates from the
387 diversity of circulating clades months in advance of vaccine composition meetings to have time to
388 grow virus in cells and eggs and measure antigenic drift with serological assays (*Morris et al., 2018*;
389 *Loes et al., 2024*). Earlier detection of viral sequences with important antigenic substitutions could
390 determine whether corresponding vaccine candidates are available at the time of the vaccine selec-
391 tion meeting or not. Newer methods to estimate influenza fitness use experimental measurements
392 of viral escape from human sera (*Lee et al., 2019*; *Welsh et al., 2024*; *Meijers et al., 2025*; *Kikawa*
393 *et al., 2025*), measurements of viral stability and cell entry (*Yu et al., 2025*), or sequences from neu-
394 raminidase, the other primary surface protein associated with antigenic drift (*Meijers et al., 2025*).
395 These methodological improvements all depend fundamentally on timely genomic surveillance
396 efforts and the GISAID EpiFlu database to identify relevant influenza variants to include in their
397 experiments. Finally, our results here reflect uncorrelated submission lags for each sequence, but
398 actual lags can strongly correlate between sequences from the same originating and submitting
399 labs. These correlated lags could further decrease the accuracy of frequency estimates beyond
400 our more conservative estimates. More rapid sequence submission will improve our understand-
401 ing of the present and give decision-makers more choices for new vaccines. Such reductions in
402 submission lags depend on substantial, sustained funding and capacity building globally.

403 ## Methods and Materials

404 ### Selection of natural influenza A/H3N2 HA sequences

405 We downloaded all A/H3N2 HA sequences and metadata from GISAID's EpiFlu database (*Shu and*
406 *McCauley, 2017*) as of November 2023. We evenly sampled sequences geographically and tempo-
407 rally as previously described (*Huddleston et al., 2020*). Briefly, we selected 90 sequences per month,
408 evenly sampling from major continental regions (Africa, Europe, North America, China, South Asia,
409 Japan and Korea, Oceania, South America, Southeast Asia, and West Asia) and excluding sequences
410 labeled as egg-passaged or missing complete date annotations. For our forecasting analyses, we
411 selected sequences collected between April 1, 2005 and October 1, 2019. This sampling approach
412 accounts for known regional biases in sequence availability through time (*McCarron et al., 2022*)
413 and makes inference of divergence and time trees computationally tractable. This approach also
414 exactly matches our previous study where we first trained the forecast models used in this study
415 (*Huddleston et al., 2020*), allowing us to reuse those previously trained models. With this sub-
416 sampling approach, we selected between 7% (Europe) and 91% (Southeast Asia) of all available
417 sequences per region across the entire study period with an average of 50% and median of 52%
418 across all 10 regions (*Figure 1—figure Supplement 4*). To verify the reproducibility and robustness
419 of our results, we reran the full forecasting analysis with a high-density subsampling scheme that
420 selected 270 sequences per month with the same even sampling across regions and time as the
421 original scheme. With this approach, we selected between 17% (Europe) and 97% (Southeast Asia)
422 of all available sequences per region with an average of 72% sampled and a median of 83% (*Fig-*
423 *ure 1—figure Supplement 4*C).

424 ### Simulation of influenza A/H3N2-like HA sequences

425 We simulated A/H3N2-like populations as previously described (*Huddleston et al., 2020*). Briefly,
426 we simulated A/H3N2 HA sequences with SANTA-SIM (*Jariani et al., 2019*) for 10,000 generations
427 or 50 years at 200 generations per year. We discarded the first 10 years of simulated data as a
428 burn-in period and used the next 30 years of the remaining data for our analyses. We sampled 90

429 viruses per month to match the sampling density of natural populations.

Estimating and assigning submission lags

We estimated the lag between sample collection and submission of A/H3N2 hemagglutinin (HA)
sequences to the GISAID EpiFlu database (*Shu and McCauley, 2017*) by calculating the difference in
GISAID-annotated submission date and collection date in days for samples collected between Jan-
uary 1, 2019 and January 1, 2020 and with a submission date prior to October 1, 2020. We selected
this period of time as representative of modern genomic surveillance efforts prior to changes in cir-
culation patterns of influenza caused by the SARS-CoV-2 pandemic. Of the 104,392 HA sequences
in GISAID EpiFlu, 11,222 (11%) were collected during this period with a mean submission lag of 98
days (∼3 months) and a median lag of 74 days. Only 11% of sequences (N=1,210) were submitted
within 4 weeks of collection, and only 36% (N=4,057) were submitted within 8 weeks (*Figure 1*A,
purple).

We modeled the shape of the observed lag distribution as a gamma distribution using a max-
imum likelihood fit from SciPy 1.10.1 (*Virtanen et al., 2020*). With this approach, we estimated a
shape parameter of 1.76, a scale parameter of 53.18, and location parameter of 3.98. The product
of these shape and scale values corresponded to a mean lag of 93.76 days (*Figure 1*A, green). To
assign realistic submission lags to each sample in our analysis, we randomly sampled from this
gamma distribution and calculated a "realistic submission date" by adding the sampled lag in days
to the observed collection date. This approach allowed us to assign realistic lags to natural and sim-
ulated populations without the biases and autocorrelations associated with historical submission
patterns across different submitting labs.

Based on the observed rapid submission of SARS-CoV-2 genomes during the first years of the
pandemic, we expected that an achievable "ideal" submission lag for seasonal influenza sequences
would have a 1-month average lag instead of the observed ∼3-month lag from the pre-pandemic
period. We modeled this ideal submission lag distribution by dividing the gamma shape parameter
by 3 to get a value of 0.59 and a corresponding mean lag of 31.25 days (*Figure 1*A, orange). This ap-
proach effectively shifted the realistic gamma toward zero, while maintaining the relatively longer
upper tail of the distribution. To assign ideal submission lags to each sample in our analysis, we
randomly sampled from this modified gamma distribution and added the sampled lag in days to
the observed collection date. Additionally, we required that each sample's "ideal" lag be less than
or equal to its "realistic" lag.

To estimate the effect of increased global sequencing capacity associated with the response to
the SARS-CoV-2 pandemic, we summarized the lag distribution for sequences submitted to GISAID
EpiFlu between January 1, 2022 and January 1, 2023. During this period, global influenza circulation
had rebounded to its prepandemic level and 26,394 HA sequences were collected. The mean and
median submission lags during this period were 76 and 62 days, respectively, representing a trend
toward reduced lags compared to the prepandemic era (*Figure 1—figure Supplement 1*).

Phylogenetic inference

We inferred time-scaled phylogenetic trees for HA sequences as previously described (*Huddleston*
et al., 2020). Briefly, we aligned sequences with MAFFT v7.520 (*Katoh et al., 2002*; *Katoh and Stand-*
ley, 2013) using the `augur align` command in Augur v22.3.0 (*Huddleston et al., 2021*). We inferred
phylogenies with IQ-TREE v2.2.3 (*Nguyen et al., 2014*) using the `augur tree` command with IQ-TREE
parameters of `-ninit 2 -n 2 -me 0.05` and a general time reversible (GTR) model. We inferred
time-resolved phylogenies with TreeTime v0.10.1 (*Sagulenko et al., 2018*) with the `augur refine`
command.

Forecasting with different forecast horizons

475 We tested the effect of forecasting future influenza populations at forecast horizons of 3, 6, 9, and
476 12 months (*Figure 1*B). Previously, we produced forecasts every 6 months starting from October

1 and April 1 and predicting 12 months into the future (*Huddleston et al., 2020*). To support fore-
casts in 3-month intervals, we produced annotated time trees for 6 years of HA sequences every
3 months with data available up to the first day of January, April, July, and October. We produced
these trees for each timepoint with three different lag scenarios: no lag, ideal lag, and realistic lag.
For each scenario, we selected sequences for analysis at a given timepoint based on their collection
date, ideal submission date, or realistic submission date, respectively. This experimental design
produced forecasts for three lag types at each of the four forecast horizons (e.g., *Figure 1*B, blue,
green, and orange initial timepoints for the 3-month forecast horizon).

Since reliable submission dates were not available prior to April 2005, our analysis of natural
A/H3N2 sequences spanned from April 1, 2005 to October 1, 2019. To simplify the data required for
these analyses, we produced forecasts of natural A/H3N2 populations with our best sequence-only
model from our prior work (*Huddleston et al., 2020*), a composite model based on local branch-
ing index (LBI) (*Neher et al., 2014*) and mutational load (*Łuksza and Lässig, 2014*). For simulated
A/H3N2-like populations, we produced forecasts with the "true fitness" model that relies on the
normalized fitness value of each simulated sample.

Each forecast generated a predicted future frequency per sequence in the initial timepoint's
tree. As in our prior work, we calculated the earth mover's distance (*Rubner et al., 1998*) between
the predicted and observed future populations using HA amino acid sequences from initial and
future timepoints, predicted future frequencies from the initial timepoint, and observed future fre-
quencies from future timepoint. For the future timepoint, we used data from the "no lag" scenario
as our truth set, regardless of the lag scenario for the initial timepoint. This design allowed us to
measure the effect of ideal and realistic submission lags on forecast accuracy relative to a scenario
with no lags.

Defining clades

Official clade definitions do not exist for all time periods of our analysis of A/H3N2 populations and
do not exist at all for simulated A/H3N2-like populations. Therefore, we defined clades *de novo* for
both population types with the same clade assignment algorithm used to produce "subclades"
for recent seasonal influenza vaccine composition meeting reports (*Huddleston et al., 2024*). The
complete algorithm description and implementation is available at https://github.com/neherlab/
flu_clades. Briefly, the algorithm scores each node in a phylogenetic tree based on three criteria
including the number of child nodes descending from the current node, the number of epitope
substitutions on the branch leading to the current node, and the number of amino acid mutations
since the last clade assigned to an ancestor in the tree. After assigning and normalizing scores, the
algorithm traverses the tree in preorder, assigning clade labels to each internal node whose score
exceeds a predefined threshold of 1.0. Clade labels follow a hierarchical nomenclature inspired
by Pangolin (*O'Toole et al., 2021*) such that the first clade in the tree is named "A" and its first
immediate descendant is named "A.1". For each population type, we applied this algorithm to a
single phylogeny representing all HA sequences present in our analysis. This approach allowed us
to produce a single clade assignment per sequence and easily identify related sequences between
initial and future timepoints using the hierarchical clade nomenclature.

Estimating current and future clade frequencies

We estimated clade frequencies with a kernel density estimation (KDE) approach as previously de-
scribed (*Huddleston et al., 2020*) with the `augur frequencies` command (*Huddleston et al., 2021*).
Briefly, we represented each sequence in a given phylogeny by a Gaussian kernel with a mean
at the sequence's collection date and a variance of two months. We estimated the frequency of
each sequence at each timepoint by calculating the probability density function of each KDE at that
timepoint and normalizing the resulting values to sum to one.

We calculated clade frequencies for each initial timepoint in our analysis by first summing the
frequencies of individual sequences in a given timepoint's tree by the clade assigned to each se-

quence and then summing the frequencies for each clade and its descendants to obtain nested clade frequencies. To inspect the effects of submission lags on clade frequency estimates, we calculated the clade frequency error per timepoint and clade by subtracting the clade frequency estimated with ideal or realistic lagged sequence submission from the corresponding clade frequency without lags. We compared the effects of submission lags for clades of different sizes by filtering clades by their frequency estimated without lags to small clades (>0% and <10%) and large clades ($\geq$10%).

To estimate the accuracy of clade frequency forecasts, we needed to calculate the predicted and observed future clade frequencies for each combination of lag type, initial timepoint, and future timepoint in the analysis. We calculated predicted future frequencies for all clades that existed at given initial timepoint and lag type by first summing the predicted future frequency per sequence by the clade assigned to each sequence and then summing the predicted frequencies for each clade and its descendants. Clades that existed at any given future timepoint were not always represented at a corresponding initial timepoint either because the clades had not emerged yet or sequences for those clades had a lagged submission. For this reason, we calculated observed future clade frequencies in a multi-step process. First, we calculated the frequencies of clades observed at the future timepoint without submission lag by summing the individual frequencies of all sequences in each clade. Then, we mapped each future clade to its most derived ancestral clade that circulated at the initial timepoint by progressively removing suffixes from the future clade's label until we found a match in the initial timepoint. For example, if the future timepoint had a clade named A.1.1.3 and the initial timepoint had the ancestral clade A.1, we would test for the presence of A.1.1.3, A.1.1, and A.1 at the initial timepoint until we found a match. The hierarchical nature of the clade assignment algorithm guaranteed that each future clade mapped directly to a clade at each initial timepoint and lag type. Finally, we summed the frequencies of future clades by their corresponding initial clades to get the observed future frequencies of clades circulating at the initial timepoint. We calculated the accuracy of clade frequency forecasts as the difference between the predicted and observed future clade frequencies.

Data and software availability

Sequence data are available from the GISAID EpiFlu Database using accessions provided in Supplemental File S1. Source code for the analysis workflow and manuscript are available in the project's GitHub repository (https://github.com/blab/flu-forecasting-delays). Supplemental data are available on Zenodo at DOI 10.5281/zenodo.17259448.

Acknowledgments

We gratefully acknowledge the authors, originating and submitting laboratories of the sequences from the GISAID EpiFlu Database (*Shu and McCauley, 2017*) on which this research is based. A list of sequence accessions, authors, and labs appear in the Supplemental Material. We thank Katie Kistler and Marlin Figgins for their comments on early versions of this manuscript and Richard A. Neher for the development of tools for hierarchical clade nomenclature. This work was funded by NIAID R01 AI165821-01. TB is a Howard Hughes Medical Institute Investigator.

Author contributions

JH designed and implemented experiments, analyzed results, and wrote the manuscript. TB edited the manuscript.

Competing interests

The authors declare that no competing interests exist.

571 **Supplemental File S1.** GISAID accessions and metadata including originating and submitting labs

572 for natural strains used across all timepoints.

References

574 **Abousamra E**, Figgins M, Bedford T. Fitness models provide accurate short-term forecasts of SARS-CoV-2
575 variant frequency. PLOS Computational Biology. 2024 09; 20(9):1–20. https://doi.org/10.1371/journal.pcbi.
576 1012443, doi: 10.1371/journal.pcbi.1012443.

577 **Baden LR**, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, Diemert D, Spector SA, Rouphael N, Creech CB,
578 McGettigan J, Khetan S, Segall N, Solis J, Brosz A, Fierro C, Schwartz H, Neuzil K, Corey L, Gilbert P, et al.
579 Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med. 2021 Feb; 384(5):403–416.

580 **Bedford T**, Riley S, Barr IG, Broor S, Chadha M, Cox NJ, Daniels RS, Gunasekaran CP, Hurt AC, Kelso A, Klimov A,
581 Lewis NS, Li X, McCauley JW, Odagiri T, Potdar V, Rambaut A, Shu Y, Skepner E, Smith DJ, et al. Global circulation
582 patterns of seasonal influenza viruses vary with antigenic drift. Nature. 2015 Jun; 523(7559):217–220. http:
583 //dx.doi.org/10.1038/nature14460, doi: 10.1038/nature14460.

584 **Black A**, MacCannell DR, Sibley TR, Bedford T. Ten recommendations for supporting open pathogen genomic
585 analysis in public health. Nat Med. 2020 Jun; 26(6):832–841.

586 **Brazzoli M**, Magini D, Bonci A, Buccato S, Giovani C, Kratzer R, Zurli V, Mangiavacchi S, Casini D, Brito LM, De Gre-
587 gorio E, Mason PW, Ulmer JB, Geall AJ, Bertholet S. Induction of Broad-Based Immunity and Protective Efficacy
588 by Self-amplifying mRNA Vaccines Encoding Influenza Virus Hemagglutinin. J Virol. 2016 Jan; 90(1):332–344.

589 **Brito AF**, Semenova E, Dudas G, Hassler GW, Kalinich CC, Kraemer MUG, Ho J, Tegally H, Githinji G, Agoti CN,
590 Matkin LE, Whittaker C, Howden BP, Sintchenko V, Zuckerman NS, Mor O, Blankenship HM, de Oliveira T, Lin
591 RTP, Siqueira MM, et al. Global disparities in SARS-CoV-2 genomic surveillance. Nat Commun. 2022 Nov;
592 13(1):7003.

593 **Chen Z**, Azman AS, Chen X, Zou J, Tian Y, Sun R, Xu X, Wu Y, Lu W, Ge S, Zhao Z, Yang J, Leung DT, Domman
594 DB, Yu H. Global landscape of SARS-CoV-2 genomic surveillance and data sharing. Nat Genet. 2022 Apr;
595 54(4):499–507.

596 **Feldman RA**, Fuhr R, Smolenov I, Mick Ribeiro A, Panther L, Watson M, Senn JJ, Smith M, Almarsson Ö, Pujar
597 HS, Laska ME, Thompson J, Zaks T, Ciaramella G. mRNA vaccines against H10N8 and H7N9 influenza viruses
598 of pandemic potential are immunogenic and well tolerated in healthy adults in phase 1 randomized clinical
599 trials. Vaccine. 2019 May; 37(25):3326–3334.

600 **Grant R**, Sacks JA, Abraham P, Chunsuttiwat S, Cohen C, Figueroa JP, Fleming T, Fine P, Goldblatt D, Hasegawa H,
601 MacIntrye CR, Memish ZA, Miller E, Nishioka S, Sall AA, Sow S, Tomori O, Wang Y, Van Kerkhove MD, Wambo
602 MA, et al. When to update COVID-19 vaccine composition. Nat Med. 2023 Apr; 29(4):776–780.

603 **Hampson A**, Barr I, Cox N, Donis RO, Siddhivinayak H, Jernigan D, Katz J, McCauley J, Motta F, Odagiri T, Tam
604 JS, Waddell A, Webby R, Ziegler T, Zhang W. Improving the selection and development of influenza vaccine
605 viruses – Report of a WHO informal consultation on improving influenza vaccine virus selection, Hong Kong
606 SAR, China, 18–20 November 2015. Vaccine. 2017; 35(8):1104–1109. https://www.sciencedirect.com/science/
607 article/pii/S0264410X17300373, doi: https://doi.org/10.1016/j.vaccine.2017.01.018.

608 **Hay AJ**, McCauley JW. The WHO global influenza surveillance and response system (GISRS)-A future perspective.
609 Influenza Other Respir Viruses. 2018 Sep; 12(5):551–557.

610 **Huddleston J**, Barnes JR, Rowe T, Xu X, Kondor R, Wentworth DE, Whittaker L, Ermetal B, Daniels RS, McCauley
611 JW, Fujisaki S, Nakamura K, Kishida N, Watanabe S, Hasegawa H, Barr I, Subbarao K, Barrat-Charlaix P, Neher
612 RA, Bedford T. Integrating genotypes and phenotypes improves long-term forecasts of seasonal influenza
613 A/H3N2 evolution. eLife. 2020 Sep; 9:e60067. https://doi.org/10.7554/eLife.60067, doi: 10.7554/eLife.60067.

614 **Huddleston J**, Bedford T, Chang J, Lee J, Neher RA. Seasonal influenza circulation patterns and projections
615 for February 2024 to February 2025. Zenodo. 2024 Mar; https://doi.org/10.5281/zenodo.10846007, doi:
616 10.5281/zenodo.10846007.

617 **Huddleston J**, Hadfield J, Sibley TR, Lee J, Fay K, Ilcisin M, Harkins E, Bedford T, Neher RA, Hodcroft EB. Augur:
618 a bioinformatics toolkit for phylogenetic analyses of human pathogens. J Open Source Softw. 2021; 6(57).

619 **Jariani A**, Warth C, Deforche K, Libin P, Drummond AJ, Rambaut A, Matsen IV FA, Theys K. SANTA-SIM: simulating
620 viral sequence evolution dynamics under selection and recombination. Virus Evolution. 2019 Mar; 5(1).

621 **Kalia K**, Saberwal G, Sharma G. The lag in SARS-CoV-2 genome submissions to GISAID. Nat Biotechnol. 2021
622 Sep; 39(9):1058–1060.

623 **Katoh K**, Standley DM. MAFFT multiple sequence alignment software version 7: improvements in performance
624 and usability. Mol Biol Evol. 2013 Apr; 30(4):772–780.

625 **Katoh K**, Misawa K, Kuma K, Miyata T. MAFFT: a novel method for rapid multiple sequence alignment based
626 on fast Fourier transform. Nucleic Acids Research. 2002 07; 30(14):3059–3066. https://doi.org/10.1093/nar/
627 gkf436, doi: 10.1093/nar/gkf436.

628 **Kikawa C**, Loes AN, Huddleston J, Figgins MD, Steinberg P, Griffiths T, Drapeau EM, Peck H, Barr IG, Englund
629 JA, Hensley SE, Bedford T, Bloom JD. High-throughput neutralization measurements correlate strongly with
630 evolutionary success of human influenza strains. eLife. 2025 Jun; http://dx.doi.org/10.7554/eLife.106811.1,
631 doi: 10.7554/elife.106811.1.

632 **Kistler KE**, Bedford T. An atlas of continuous adaptive evolution in endemic human viruses. Cell Host Microbe.
633 2023; 31(11):1898–1909.

634 **Lässig M**, Mustonen V, Walczak AM. Predicting evolution. Nat Ecol Evol. 2017 Feb; 1(3):77.

635 **Lee JM**, Eguia R, Zost SJ, Choudhary S, Wilson PC, Bedford T, Stevens-Ayers T, Boeckh M, Hurt AC, Lakdawala SS,
636 Hensley SE, Bloom JD. Mapping person-to-person variation in viral mutations that escape polyclonal serum
637 targeting influenza hemagglutinin. Elife. 2019 Aug; 8.

638 **Loes AN**, Araceli RL, Huddleston J, Touyon L, San Wong S, Cheng SMS, Leung NHL, Hannon WW, Bedford T,
639 Cobey S, Cowling BJ, Bloom JD. High-throughput sequencing-based neutralization assay reveals how re-
640 peated vaccinations impact titers to recent human H1N1 influenza strains. Journal of Virology. 2024 Sep;
641 98(10):e00689–24. https://journals.asm.org/doi/abs/10.1128/jvi.00689-24, doi: 10.1128/jvi.00689-24.

642 **Łuksza M**, Lässig M. A predictive fitness model for influenza. Nature. 2014 Mar; 507(7490):57–61.

643 **McCarron M**, Kondor R, Zureick K, Griffin C, Fuster C, Hammond A, Lievre M, Vandemaele K, Bresee J, Xu X,
644 Dugan V, Weatherspoon V, Williams T, Vance A, Fry A, Samaan M, Fitzner J, Zhang W, Moen A, Wentworth D,
645 et al. United States Centers for Disease Control and Prevention support for influenza surveillance, 2013–2021.
646 Bulletin of the World Health Organization. 2022 Jun; 100(06):366–374. http://dx.doi.org/10.2471/BLT.21.
647 287253, doi: 10.2471/blt.21.287253.

648 **Meijers M**, Ruchnewitz D, Eberhardt J, Łuksza M, Lässig M. Population immunity predicts evolutionary trajec-
649 tories of SARS-CoV-2. Cell. 2023 Nov; 186(23):5151–5164.

650 **Meijers M**, Ruchnewitz D, Eberhardt J, Karmakar M, Łuksza M, Lässig M. In: Concepts and Methods for Pre-
651 dicting Viral Evolution Springer US; 2025. p. 253–290. http://dx.doi.org/10.1007/978-1-0716-4326-6_14, doi:
652 10.1007/978-1-0716-4326-6_14.

653 **Morris DH**, Gostic KM, Pompei S, Bedford T, Łuksza M, Neher RA, Grenfell BT, Lässig M, McCauley JW. Predictive
654 modeling of influenza shows the promise of applied evolutionary biology. Trends Microbiol. 2018 Oct; .

655 **Mulligan MJ**, Lyke KE, Kitchin N, Absalon J, Gurtman A, Lockhart S, Neuzil K, Raabe V, Bailey R, Swanson KA, Li
656 P, Koury K, Kalina W, Cooper D, Fontes-Garfias C, Shi PY, reci Ö, Tompkins KR, Walsh EE, Frenck R, et al. I/II
657 study of COVID-19 RNA vaccine BNT162b1 in adults. Nature. 2020 Oct; 586(7830):589–593.

658 **Neher RA**, Russell CA, Shraiman BI. Predicting evolution from the shape of genealogical trees. Elife. 2014 Nov;
659 3:e03568.

660 **Nguyen LT**, Schmidt HA, von Haeseler A, Minh BQ. IQ-TREE: A fast and effective stochastic algorithm for
661 estimating maximum-likelihood phylogenies. Molecular Biology and Evolution. 2014 11; 32(1):268–274.
662 https://doi.org/10.1093/molbev/msu300, doi: 10.1093/molbev/msu300.

663 **O'Toole A**, Scher E, Underwood A, Jackson B, Hill V, McCrone JT, Colquhoun R, Ruis C, Abu-Dahab K, Taylor B,
664 Yeats C, du Plessis L, Maloney D, Medd N, Attwood SW, Aanensen DM, Holmes EC, Pybus OG, Rambaut A.
665 Assignment of epidemiological lineages in an emerging pandemic using the pangolin tool. Virus Evol. 2021;
666 7(2):veab064.

Pardi N, Parkhouse K, Kirkpatrick E, McMahon M, Zost SJ, Mui BL, Tam YK, ó K, Barbosa CJ, Madden TD, Hope MJ, Krammer F, Hensley SE, Weissman D. Nucleoside-modified mRNA immunization elicits influenza virus hemagglutinin stalk-specific antibodies. Nat Commun. 2018 Aug; 9(1):3361.

Petrova VN, Russell CA. The evolution of seasonal influenza viruses. Nature Reviews Microbiology. 2018 Jan; 16(1):47–60. https://doi.org/10.1038/nrmicro.2017.118, doi: 10.1038/nrmicro.2017.118.

Petsch B, Schnee M, Vogel AB, Lange E, Hoffmann B, Voss D, Schlake T, Thess A, Kallen KJ, Stitz L, Kramps T. Protective efficacy of in vitro synthesized, specific mRNA vaccines against influenza A virus infection. Nat Biotechnol. 2012 Dec; 30(12):1210–1216.

Pfizer, A PHASE 3, RANDOMIZED, OBSERVER-BLINDED STUDY TO EVALUATE THE EFFICACY, SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER; 2022. https://clinicaltrials.gov/study/NCT05540522, nCT05540522 (Registry Identifier).

Rubner Y, Tomasi C, Guibas LJ. A metric for distributions with applications to image databases. In: *Sixth International Conference on Computer Vision (IEEE Cat. No.98CH36271)*; 1998. p. 59–66. doi: 10.1109/ICCV.1998.710701.

Sagulenko P, Puller V, Neher RA. TreeTime: Maximum-likelihood phylodynamic analysis. Virus Evolution. 2018 01; 4(1). https://doi.org/10.1093/ve/vex042, doi: 10.1093/ve/vex042.

Shu Y, McCauley J. GISAID: Global initiative on sharing all influenza data – from vision to reality. Eurosurveillance. 2017; 22(13).

Smith DJ, Lapedes AS, de Jong JC, Bestebroer TM, Rimmelzwaan GF, Osterhaus ADME, Fouchier RAM. Mapping the antigenic and genetic evolution of influenza virus. Science. 2004 Jul; 305(5682):371–376.

Soens M, Ananworanich J, Hicks B, Lucas KJ, Cardona J, Sher L, Livermore G, Schaefers K, Henry C, Choi A, Avanesov A, Chen R, Du E, Pucci A, Das R, Miller J, Nachbagauer R. A phase 3 randomized safety and immunogenicity trial of mRNA-1010 seasonal influenza vaccine in adults. Vaccine. 2025; 50:126847. https://www.sciencedirect.com/science/article/pii/S0264410X25001446, doi: https://doi.org/10.1016/j.vaccine.2025.126847.

Steinbrück L, Klingen TR, McHardy AC. Computational prediction of vaccine strains for human influenza A (H3N2) viruses. J Virol. 2014 Oct; 88(20):12123–12132.

Virtanen P, Gommers R, Oliphant TE, Haberland M, Reddy T, Cournapeau D, Burovski E, Peterson P, Weckesser W, Bright J, van der Walt SJ, Brett M, Wilson J, Millman KJ, Mayorov N, Nelson ARJ, Jones E, Kern R, Larson E, Carey CJ, et al. SciPy 1.0: fundamental algorithms for scientific computing in Python. Nature Methods. 2020 Mar; 17(3):261–272. https://www.nature.com/articles/s41592-019-0686-2, doi: 10.1038/s41592-019-0686-2, number: 3 Publisher: Nature Publishing Group.

Welsh FC, Eguia RT, Lee JM, Haddox HK, Galloway J, Van Vinh Chau N, Loes AN, Huddleston J, Yu TC, Quynh Le M, Nhat NTD, Thi Le Thanh N, Greninger AL, Chu HY, Englund JA, Bedford T, Matsen t F A, Boni MF, Bloom JD. Age-dependent heterogeneity in the antigenic effects of mutations to influenza hemagglutinin. Cell Host Microbe. 2024 Jul; .

Wong SS, Webby RJ. Traditional and new influenza vaccines. Clin Microbiol Rev. 2013 Jul; 26(3):476–492.

World Health Organization. Seasonal influenza fact sheet. Available at http://www.who.int/mediacentre/factsheets/fs211/en/; 2014.

Yamayoshi S, Kawaoka Y. Current and future influenza vaccines. Nature Medicine. 2019 Feb; 25(2):212–220. https://doi.org/10.1038/s41591-018-0340-z, doi: 10.1038/s41591-018-0340-z.

Yu TC, Kikawa C, Dadonaite B, Loes AN, Englund JA, Bloom JD. Pleiotropic mutational effects on function and stability constrain the antigenic evolution of influenza hemagglutinin. . 2025 May; http://dx.doi.org/10.1101/2025.05.24.655919, doi: 10.1101/2025.05.24.655919.

Figure 1—figure supplement 1. Distribution of submission lags in days for the pre-pandemic era (2019-2020 in blue) and pandemic era (2022-2023 in orange). Vertical dashed lines represent mean lags for each distribution.

Figure 1—figure supplement 2. A) Number of A/H3N2 sequences available per timepoint and lag type. B) Proportion of all A/H3N2 sequences without lag per timepoint and lag type.

Figure 1—figure supplement 3. A) Number of simulated A/H3N2-like sequences available per timepoint and lag type. B) Proportion of all simulated A/H3N2-like sequences without lag per timepoint and lag type.

Figure 1—figure supplement 4. A) Number of all available sequences per region and year in the GISAID EpiFlu database for the study period between April 1, 2005 and October 1, 2019. B) Proportion of sequences sampled per region and year with even subsampling across regions and year/month combinations at 90 viruses per month. C) Proportion of sequences sampled per region and year with even subsampling across regions and year/month combinations at 270 viruses per month.

Figure 2—figure supplement 1. Distance to the future per timepoint (AAs) for simulated A/H3N2-like populations by forecast horizon and submission lag type based on forecasts from the "true fitness" model.
Figure 2—figure supplement 1—source data 1. Distance to the future for simulated A/H3N2-like populations; see `simulated_distances_to_the_future.csv` at https://doi.org/10.5281/zenodo.17259448.

Figure 2—figure supplement 2. Optimal distance to the future per timepoint (AAs) for natural A/H3N2 populations by forecast horizon and submission lag type based on posthoc empirical fitness of the initial population.

Figure 2—figure supplement 3. Optimal distance to the future per timepoint (AAs) for simulated A/H3N2-like populations by forecast horizon and submission lag type based on posthoc empirical fitness of the initial population.

Figure 3—figure supplement 1. Clade frequency errors between simulated A/H3N2-like HA populations with ideal or realistic submission lags and populations without any submission lag.
Figure 3—figure supplement 1—source data 1. Current and future clade frequencies for simulated A/H3N2-like populations by forecast horizon and submission lag type; see `simulated_clade_frequencies.csv` at https://doi.org/10.5281/zenodo.17259448.

Figure 4—figure supplement 1. Absolute forecast clade frequency errors for simulated A/H3N2-like HA populations by forecast horizon in months and submission lag type (none, ideal, or realistic) for A) small clades (<10% initial frequency) and B) large clades (≥10% initial frequency).

Figure 4—figure supplement 2. Forecast clade frequency errors for natural A/H3N2 HA populations by forecast horizon in months and submission lag type (none, ideal, or realistic) for A) small clades (<10% initial frequency) and B) large clades (≥10% initial frequency).

Figure 4—figure supplement 3. Forecast clade frequency errors for simulated A/H3N2-like HA populations by forecast horizon in months and submission lag type (none, ideal, or realistic) for A) small clades (<10% initial frequency) and B) large clades (≥10% initial frequency).

Figure 5—figure supplement 1. Distribution of total absolute clade frequency errors summed across clades per future timepoint for A/H3N2 populations. We calculated the effects of interventions as the difference between these values per future timepoint under the status quo (12-month forecast horizon and realistic submission lag) and specific interventions.

Figure 5—figure supplement 2. Improvement of clade frequency errors for simulated A/H3N2-like populations between the status quo and realistic interventions.
Figure 5—figure supplement 2—source data 1. Differences in total absolute clade frequency error per future timepoint and clade between the status quo and realistic interventions for simulated A/H3N2-like populations; see `simulated_effects_of_realistic_interventions.csv` at https://doi.org/10.5281/zenodo.17259448.

724

Figure 5—figure supplement 3. Distribution of total absolute clade frequency errors summed across clades per future timepoint for simulated A/H3N2-like populations.

725

Figure 5—figure supplement 4. Improvement of distances to the future (AAs) for A/H3N2 populations between the status quo (12-month forecast horizon and realistic submission lags) and realistic interventions. The effects of interventions are the differences between distances to the future per future timepoint under the status quo and specific interventions.

Figure 5—figure supplement 4—source data 1. Improvement of distances to the future per future timepoint for A/H3N2 populations; see `h3n2_effects_of_realistic_interventions_on_distances_to_the_future.csv` at https://doi.org/10.5281/zenodo.17259448.

726

Figure 5—figure supplement 5. Improvement of distances to the future (AAs) for simulated A/H3N2-like populations between the status quo (12-month forecast horizon and realistic submission lags) and realistic interventions. The effects of interventions are the differences between distances to the future per future timepoint under the status quo and specific interventions.

Figure 5—figure supplement 5—source data 1. Improvement of distances to the future per future timepoint for simulated A/H3N2-like populations; see `simulated_effects_of_realistic_interventions_on_distances_to_the_future.csv` at https://doi.org/10.5281/zenodo.17259448.

Figure 6—figure supplement 1. Improvement of optimal distances to the future (AAs) for simulated A/H3N2-like populations between the status quo (12-month forecast horizon and realistic submission lags) and realistic interventions.

Figure 6—figure supplement 1—source data 1. Improvement of optimal distances to the future per future timepoint for simulated A/H3N2-like populations; see `simulated_optimal_effects_of_realistic_interventions_on_distances_to_the_future.csv` at https://doi.org/10.5281/zenodo.17259448.

Figure 6—figure supplement 2. Improvement of optimal distances to the future (AAs) for A/H3N2 populations between the status quo (12-month forecast horizon and realistic submission lags) and realistic interventions using forecasts based on sampling 270 viruses per month instead of the 90 viruses-per-month sampling used in the main results.

Figure 6—figure supplement 2—source data 1. Improvement of optimal distances to the future per future timepoint for A/H3N2 populations with higher density sampling; see `h3n2_high_density_optimal_effects_of_realistic_interventions_on_distances_to_the_future.csv` at https://doi.org/10.5281/zenodo.17259448.

Figure 6—figure supplement 3. Improvement of optimal distances to the future (AAs) for A/H3N2 populations compared to the Shannon entropy of clade frequencies (estimated without submission lags) at the future timepoint being forecast to. Panel titles include the Pearson r value between the improvement in distance and the future clade entropy.

Figure 6—figure supplement 3—source data 1. Improvement of optimal distances to the future for A/H3N2 populations compared to the Shannon entropy of clade frequencies at the future timepoint; see `h3n2_optimal_effects_of_realistic_interventions_on_distances_to_the_future_by_future_clade_entropy.csv` at https://doi.org/10.5281/zenodo.17259448.

Figure 6—figure supplement 4. Improvement of optimal distances to the future (AAs) for A/H3N2 populations by intervention and the hemisphere with an active season during the future timepoint being predicted. We labeled future timepoints that occurred in October or January as "Northern" and "Southern" if the dates were in April or July.